

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/6543167>

# Role of the Chemical Interactions of the Agonist in Controlling $\alpha$ -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptor Activation †

ARTICLE *in* BIOCHEMISTRY · MARCH 2007

Impact Factor: 3.02 · DOI: 10.1021/bi062270l · Source: PubMed

CITATIONS

16

READS

29

5 AUTHORS, INCLUDING:



**Kimberly A Mankiewicz**

University of Texas Medical School

14 PUBLICATIONS 112 CITATIONS

[SEE PROFILE](#)



**Vasanthi Jayaraman**

University of Texas Health Science Center at ...

76 PUBLICATIONS 1,089 CITATIONS

[SEE PROFILE](#)

Published in final edited form as:

*Biochemistry*. 2007 February 6; 46(5): 1343–1349.

## Role of the chemical interactions of the agonist in controlling AMPA receptor activation

Kimberly A. Mankiewicz, Anu Rambhadran, Mei Du, Gomathi Ramanoudjame, and Vasanthi Jayaraman\*

*Department of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, Texas, 77030*

### Abstract

$\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors are the main excitatory neurotransmitter receptors in the mammalian central nervous system. Structures of the isolated ligand binding domain of this receptor have provided significant insight into the large scale conformational changes, which when propagated to the channel segments leads to receptor activation. However, in order to establish the role of specific molecular interactions in controlling such fine details as the magnitude of the functional response, we have used a multiscale approach, where changes at specific moieties of the agonists have been studied by vibrational spectroscopy, while large scale conformational changes have been studied using fluorescence resonance energy transfer (FRET) investigations. By exploiting the wide range of activations by the agonists, glutamate, kainate, and AMPA, for the wild type, Y450F, and L650T mutants and by using the multiscale investigation, we show that the strength of the interactions at the  $\alpha$ -amine group of the agonist with the protein in all but one case tracks the extent of activation. Since the  $\alpha$ -amine group forms bridging interactions at the cusp of the ligand binding cleft this appears to be a critical interaction through which the agonist controls the extent of activation of the receptor.

$\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, a member of the ionotropic glutamate receptor family, are the main mediators of fast excitatory synaptic transmission in the mammalian central nervous system. Signal transmission is initiated by glutamate binding to an extracellular ligand binding domain, which leads to the formation of cation specific transmembrane channels (1–6). Large scale expression of the isolated extracellular ligand binding domain (S1S2) has led the way for detailed structural studies of this domain. X-ray (7–10), nuclear magnetic resonance (NMR) (4,11–13), and vibrational spectroscopic (14–16) investigations using this soluble protein have provided significant insight into the relationship between structure and function in this subtype.

The structures of S1S2 show a graded cleft closure conformational change upon binding agonists with varying efficacy in the bilobed ligand binding domain (9,10). The extent of cleft closure induced by a given agonist in most cases exhibits a direct correlation to the extent of activation of the receptor, suggesting that this is one of the possible modes of coupling between the ligand binding domain and opening of the ion channel. Vibrational spectroscopic investigations using the S1S2 protein provide a more detailed view of the specific interactions between the agonist and the extracellular ligand binding domain and their role in the functioning of the receptor. The frequency shifts in the asymmetric carboxylate vibrational mode, which is sensitive to the strength of the non-covalent interactions at this moiety, indicate that partial

\*Address correspondence to: Vasanthi Jayaraman, Department of Integrative Biology and Pharmacology, University of Texas Health Science Center, 6431 Fannin St., Houston, Texas, 77030, Tel: 713-500-6236; Fax: 713-500-7444; E-mail: vasanthi.jayaraman@uth.tmc.edu.

agonist kainate has stronger interactions between its  $\alpha$ -carboxylate group and protein relative to full agonists AMPA and glutamate, while the SH stretching vibration of Cys 425, which is a good probe of the strength of the interactions at the  $\alpha$ -amine group of the agonists due to its proximity to this group, indicates stronger interactions between the  $\alpha$ -amine group of the ligand with the protein for AMPA and glutamate relative to the strength of interactions for kainate. The vibrational studies (14,15), when placed in the context of the X-ray crystallography (8,9) and NMR (4,11–13) structures, appear to suggest that stronger interactions at the  $\alpha$ -amine group with a concomitant decrease in the strength of the interactions at the  $\alpha$ -carboxylate group for a ligand correlates to larger cleft closure and full agonism. Weaker interactions at the  $\alpha$ -amine group accompanied by an increase in the strength of the interactions at the  $\alpha$ -carboxylate group for a ligand results in lesser cleft closure, as compared to the full agonists, and a partial agonist response. Using this background on the wild type proteins (14,15), here we have studied the role of the interactions between the agonist and protein in more detail by using the Y450F and L650T mutants that provide a wide range of activations for the three agonists glutamate, kainate, and AMPA, thus allowing for detailed comparisons of the specific ligand-protein interactions, cleft closure, and activation to deduce the relationship between these three factors in receptor function.

The Y450 residue is conserved among all AMPA and kainate receptors, and the L650 residue is conserved among all AMPA receptors and is replaced by a valine in kainate receptors (17). Crystal structures of the kainate bound form of the GluR2-S1S2 protein suggest that the kainate is sterically hindered by the Y450 and L650 residues, allowing only for partial cleft closure in the GluR2-S1S2 protein (9,18). This steric hinderance is thought to be one of the reasons why kainate is a partial agonist. This hypothesis is strengthened by the fact that electrophysiological investigations of the Y450 (A, W) and L650 (T,V) mutations, which are expected to either introduce more flexibility in the ligand binding domain at the Y450 site or decrease the size of the L650 residue, show an increase in kainate activation (18–20). X-ray structures are available for the kainate bound forms of Y450W(19) and L650T(18) mutants, and these structures show that the increase in activation is accompanied by an increase in the degree of cleft closure relative to the degree of cleft closure observed in the kainate bound form of the wild type S1S2 protein. The AMPA and glutamate bound forms of the L650T mutant, on the other hand, do not follow the same trends as the wild type protein, and on average the AMPA bound state of the mutant is more closed than the glutamate bound state, while the activation by AMPA is significantly lower than that by glutamate (18,20). Since in this mutant the cleft closure versus activation correlation is the reverse of that observed in the wild type protein, the mechanism that dictates the subtleties of the differences in activation between AMPA and glutamate for this mutant protein is still largely unknown.

Here we have performed a multiscale analysis where the changes in the specific interactions are correlated to changes in the cleft closure conformational changes as well as receptor activation using the Y450F and L650T mutants with the goal of understanding the role of the agonist-protein interactions in mediating the cleft closure conformational changes and receptor activation. The Y450F mutation was chosen instead of the Y450W or Y450A mutations since the Y450F-S1S2 protein is relatively more stable than the Y450W-S1S2 or the Y450A-S1S2. The activation profile as well as the extent of cleft closure have been previously reported for the L650T mutant (18,20), and hence here we have determined the activation profile and extent of cleft closure for the Y450F mutation for the three agonists glutamate, kainate, and AMPA. Additionally, vibrational spectra were obtained for the three agonists bound to the Y450F-S1S2 and L650T-S1S2 proteins.

## Materials and methods

### S1S2 Y450F and S1S2 L650T Preparation and Purification

The S1S2J plasmid was generously provided by Dr. Eric Gouaux (Oregon Health and Sciences University, Portland, OR). The Y450F and L650T mutations were introduced using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). The Y450F and L650T mutants of GluR2-S1S2 (Y450F-S1S2 and L650T-S1S2) were expressed and purified as previously detailed (18). In brief, the plasmids were expressed in *E. coli* Origami B(DE3) cells. After centrifugation and clarification, the protein was purified on a Ni-NTA HiTrap column (GE Healthcare Life Sciences). The His-tag was removed by thrombin digestion and further purified using a SP-Sepharose column (GE Healthcare Life Sciences).

The binding properties of the wild type and Y450F were determined by measuring the tryptophan fluorescence as outlined in Cheng et al. (21). The  $K_d$  values determined by these fluorescence measurements for AMPA, glutamate, and kainate binding to the wild type and Y450F mutant S1S2 proteins are listed in (Supplementary Table 1).

### Fluorophore labeling

0.5  $\mu$ M protein in phosphate buffered saline with 1 mM glutamate (Sigma-Aldrich) was labeled with a 1:1 ratio of the maleimide derivatives of fluorescein (Biotium, Hayward, CA) and diethylenetriaminepentaacetic acid chelate of terbium (DTPA-Tb) (Invitrogen). The protein was then dialyzed extensively against phosphate buffered saline and used for FRET measurements.

### Fluorescence measurements

Fluorescence measurements were obtained using a *TimeMaster*<sup>TM</sup> Model TM-3/2003 (Photon Technologies, Inc., Lawrenceville, NJ). The energy source was a nitrogen laser system coupled by a fiber optic to the sample compartment. The scattered light was passed through a monochromator to a stroboscopic detector. Data were collected using Felix 32 software (Photon Technologies, Inc., Lawrenceville, NJ) and analyzed with Origin software (OriginLab Corp., Northampton, MA). The fluorescence data were obtained with at least two to three different protein samples, and for each sample the data were an average of five shots (hence the data shown is an average of ten to fifteen data points). The data from each independent sample were also fit to ensure that there were no significant differences between samples of the same protein.

### Distance calculations based on lifetime measurements

The distance between the donor and acceptor fluorophores was determined by measuring the time constants of the donor fluorescence decay in the absence of the acceptor ( $\tau_D$ ) and the sensitized emission of the acceptor as a result of energy transfer from the donor ( $\tau_{DA}$ ). The distance was then determined using equation 1 given by Förster's theory of energy transfer:

$$R = R_0 \left( \frac{\tau_{DA}}{\tau_D - \tau_{DA}} \right)^{1/6} \quad (\text{eq. 1})$$

$R_0$  was calculated using the overlap integral as described previously (20,22).

### FTIR-Difference Spectroscopy

The same protocol was used to collect the FTIR data as outlined in detail in (14,15,23). In brief, 0.25–1 mM protein in 25 mM phosphate buffer containing 250 mM NaCl and 0.02% Na<sub>3</sub> (pH 7.4) or 10mM HEPES buffer containing 100 mM NaCl (pH 7.0) was used for

measurements. D<sub>2</sub>O was used as the solvent to obtain spectra in the 1450–1800 cm<sup>-1</sup> range due to the large infrared absorption of water at  $\approx 1600$  cm<sup>-1</sup>. Water was used as the solvent to study the SH stretching vibration.

FTIR spectra were obtained using a Nicolet Nexus 870 spectrometer. An adjustable path length infrared cell holder (Aldrich) was used to obtain the spectra. Spectra were collected at 4 cm<sup>-1</sup> resolution at a constant temperature of 15°C. A path length of 50  $\mu$ m was used to obtain the spectra in the 1450–1800 cm<sup>-1</sup> range while a path length of 75  $\mu$ m was used to investigate the SH stretching. Difference spectra were obtained by subtracting the unligated form of the protein from the ligated form of the protein. Peaks from unbound agonists were subtracted using a spectrum of the agonist in buffer. Collection and manipulation of data was performed using Omnic Software and GRAMS/AI software (7.01) (Thermoelectron, Waltham, MA).

## Electrophysiological measurements

The GluR2-flip plasmid was kindly provided by Dr. Seeburg (Max Planck Institute, Heidelberg, Germany). The Y450F point mutation was introduced into the plasmid using the Stratagene QuikChange Site-Directed Mutagenesis kit (Stratagene), and the final construct was verified by sequencing the coding region of the DNA. For the electrophysiological measurements, the wild type and mutant receptors were expressed in human embryonic kidney 293 (HEK 293) cells (ATCC CRL 1573) using the same protocol as outlined in Madden et al. (24). Briefly, the cells were cultured in DMEM supplemented with 10% fetal bovine serum (Life Technologies, Bethesda, MD) and transfections were performed using Fugene 6 (Roche, Indianapolis, IN) transfection reagent, with 1–2  $\mu$ g of glutamate receptor cDNA and 0.5  $\mu$ g of plasmid containing the cDNA for green fluorescent protein. Cells were used 2–4 days after transfection.

For whole cell current recordings, transfected HEK 293 cells were voltage-clamped at a holding potential of -60 mV, and solutions were applied using a homemade U-tube mixing device that had a 100  $\mu$ m aperture. The electrode solution, for the electrophysiological measurements, contained 140 mM CaCl<sub>2</sub>, 2 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, 10 mM EGTA, 2 mM Na<sub>2</sub>ATP and 10 mM HEPES (pH 7.4). The extracellular bath solution contained 145 mM NaCl, 1.8 mM MgCl<sub>2</sub>, 3 mM KCl, 10 mM Glucose, and 10 mM HEPES (pH 7.4). Currents were amplified with an Axon 200B amplifier (Molecular Devices, CA), low pass filtered at 1 kHz. The filtered signal was digitized using a Labmaster DMA digitizing board controlled by Axon PClamp software. All the experiments were performed at room temperature.

## Results and discussion

### Functional Properties

Whole cell currents due to the activation of wild type and Y450F GluR2-flip receptors expressed in HEK 293 cells are shown in Figure 1A. The whole cell currents were mediated by saturating concentrations of glutamate (10 mM), AMPA (5 mM), and kainate (10 mM) under non-desensitizing conditions in the presence of 100  $\mu$ M cyclothiazide. To assess the relative activations by the three agonists, the average maximum peak currents were normalized to the currents mediated by 10 mM AMPA (Figure 1B). As previously reported, for the wild type receptor, kainate mediated currents are approximately 10% of the currents mediated by full agonists glutamate and AMPA (20). In contrast, kainate mediates significantly larger currents upon binding to the Y450F mutant, producing approximately 37% of the currents mediated by AMPA, indicating that the activation by kainate is larger in the Y450F mutant than in the wild type receptor. Additionally, a slight decrease is observed in the extent of activation by glutamate in the Y450F mutant relative to the extent of activation in the wild type receptor, from 95% to 87% activation relative to the currents mediated by AMPA. The whole

cell currents mediated by L650T have been previously reported (20) and are provided in Figure 1B for comparison. Kainate activation at this mutant is larger than that in wild type protein, while activation by AMPA is significantly lowered.

The larger activation of the Y450F mutant by kainate relative to the wild type receptors is consistent with the expectation that the Y450F mutation would introduce more flexibility in the ligand binding pocket due to the loss in hydrogen bonding interactions, possibly decreasing the steric hinderance by the Y450 residue that interferes with kainate binding. To establish if the flexibility in the cleft allows for a larger cleft closure by kainate in the Y450F ligand binding domain relative to the wild type protein, we have used a FRET based probe that provides a readout of the extent of cleft closure.

### Extent of cleft closure

Here Y450F-S1S2 is tagged with donor and acceptor fluorophores at positions 394 in domain 1 and 652 in domain 2. Since the donor and acceptor are tagged at sites that reflect the cleft closure conformational changes, the distances as measured by FRET provide a direct readout of the extent of cleft closure (20).

The lifetimes for the donor only and donor:acceptor tagged Y450F-S1S2 mutant protein in the apo, glutamate, AMPA, and kainate bound forms are listed in Table 1 along with the errors associated with the fits (data are shown in Supplementary Figure 1). No changes are observed in the donor only lifetimes between the apo and various ligated states while binding of the ligands results in a difference in the FRET sensitized lifetimes in the donor:acceptor tagged samples that follows the order of glutamate  $\approx$  AMPA < kainate < apo. These lifetime measurements indicate that the distance between the donor and acceptor decreases from the apo state to the ligated states, with glutamate and AMPA binding inducing a larger decrease in the distance between the donor and acceptor relative to kainate.

The distances determined by FRET for Y450F-S1S2 are plotted as a function of the extent of activation for the three agonists kainate, AMPA, and glutamate and compared with the previously reported results for the wild type S1S2 and L650T-S1S2 (20) in Figure 2. The distance between the donor and acceptor for the AMPA bound state of Y450F-S1S2 is comparable to that of the AMPA bound form of the wild type protein. This indicates similar cleft closure in the two proteins upon binding AMPA. The distance between the donor and acceptor is slightly larger for the glutamate bound form of the Y450F-S1S2 relative to the glutamate bound form of the wild type receptor, while the kainate bound form of the Y450F-S1S2 exhibits a slightly shorter distance between donor and acceptor relative to the kainate bound form of the wild type protein. However, these changes are within the error of the measurements and hence not significant. The changes in the distance between the different agonist bound forms of Y450F-S1S2, on the other hand, is significantly larger than the error associated with the measurements, and these distance changes show that Y450F-S1S2 follows the same trends as the wild type protein with a direct correlation between the extent of cleft closure and amount of activation.

The L650T mutant on the other hand, as previously reported (20), does not follow the same trends as the wild type and Y450F mutation. AMPA, a partial agonist of this mutant protein, exhibits larger cleft closure, while glutamate, which induces larger currents relative to AMPA, has a relatively more open cleft (Figure 2).

### Agonist environment in wild type and mutant protein

The difference spectra between the agonist-bound and unligated forms of the wild type, Y450F-S1S2, and L650T-S1S2 proteins, in the region of 1560  $\text{cm}^{-1}$  to 1740  $\text{cm}^{-1}$  are shown in Figure



3. As reported previously, this region of the FTIR spectrum has modes due to the carboxylates/isoxazole moieties of the agonists, as well as the amide I vibrations from the protein backbone (14,15). The asymmetric stretching vibration of the  $\alpha$ -carboxylate is assigned using  $^{13}\text{C}$  labeling at the  $\alpha$ -carboxylate position for AMPA and glutamate while the other features are assigned based on frequencies.

### Secondary structural changes

The amide I feature at  $1630\text{ cm}^{-1}$  for the glutamate and AMPA difference spectra, and at  $1625\text{ cm}^{-1}$  for the kainate difference spectra, can be assigned based on frequency to changes at  $\beta$ -sheets (14). The difference feature at this frequency is upshifted in the Y450F difference spectrum relative to the wild type difference spectrum for all the agonists, while exhibiting slight upshifts or no changes in the L650T difference spectra for the three agonists relative to the wild type spectra. This trend in the extent of upshift has no specific correlation to the extent of changes in the activation or to the extent of cleft closure and therefore most likely reflects the local perturbation due to the mutations, since similar trends are observed for a given mutation. Specifically, the larger upshifts for the Y450F mutation could arise from the larger flexibility expected for this mutant due to the loss of the hydrogen bonding network contribution of the tyrosine residue. This correlation would also be consistent with the lack of large changes in the L650T mutation, which is not expected to cause a large change in the flexibility/dynamics.

The amide I feature at  $1643/1644\text{ cm}^{-1}$ , on the other hand, appears to show a correlation to the extent of activation. The intensity of this feature is significantly lower in the difference spectrum due to AMPA and kainate binding to the L650T-S1S2 relative to the intensity of this feature in the difference spectrum due to full agonist binding (AMPA and glutamate) to the wild type protein. This decrease in intensity correlates to a decrease in activation of the receptor. Additionally, in the kainate induced difference spectra for the Y450F mutant as well as the wild type, a new band with significantly higher intensity is observed at  $1650\text{ cm}^{-1}$ . It should also be noted that although AMPA activation of the L650T mutation and kainate activation of the Y450F mutation are similar, the difference features due to AMPA binding to the L650T-S1S2 and kainate binding to Y450F-S1S2 are different. This indicates that although the same trends in the changes at the  $1643/1644\text{ cm}^{-1}$  feature are observed for both kainate and AMPA binding, the exact correlation between changes at the  $1643/1644\text{ cm}^{-1}$  feature and activation differ for the different agonists. This could arise due to subtle differences in the mechanisms of activation between these two agonists. The  $1643/1644\text{ cm}^{-1}$  frequency indicates that this feature can arise due to changes in random structures, irregular  $\beta$ -sheets, and/or solvent exposed helices (14,25). Hence this feature cannot be assigned to a specific conformational change but for a given agonist can be used as a diagnostic tool to identify the extent of agonism.

### Environment of the agonist- Interactions at the $\alpha$ -carboxylate

The frequency of the asymmetric carboxylate vibration of the  $\alpha$ -carboxylates of the agonists has previously been shown to be a probe of the strength of the non-covalent interactions between this moiety and the protein (14,15). A downshift in this feature is indicative of a relatively more favorable interaction, and conversely an upshift suggests more unfavorable interactions.

In the difference spectrum showing the asymmetric  $\alpha$ -carboxylate vibrations (Figure 3), no significant changes are observed in the frequency of the asymmetric  $\alpha$ -carboxylate vibrations for AMPA and glutamate between the wild type proteins and mutant proteins. A  $1\text{ cm}^{-1}$  downshift is observed in the L650T-S1S2 protein for AMPA and a  $1\text{ cm}^{-1}$  downshift is observed in the Y450F-S1S2 protein for glutamate relative to their frequencies in the wild type proteins. This indicates that the strengths of the non-covalent interactions between the  $\alpha$ -

carboxylates and protein may be slightly more favorable for AMPA in the L650T mutant and for glutamate in the Y450F mutant relative to that in wild type protein. The largest changes are observed in the kainate induced difference features, where  $4\text{ cm}^{-1}$  and  $5\text{ cm}^{-1}$  upshifts are observed in the frequencies of this mode in the Y450F-S1S2 and L650T-S1S2 difference spectra respectively, relative to the frequency of this mode when kainate is bound to the wild type protein. This indicates a significantly less favorable and weaker interaction at the  $\alpha$ -carboxylate of kainate with the Y450F and L650T mutants relative to its interaction with the wild type protein (14,15).

### **Cysteine 425 environment-Probe of the strength of the interactions at the $\alpha$ -amine group of the ligand**

Since the  $\alpha$ -amine group of the agonist is hydrogen bonded to Pro 478, and the backbone of the adjacent residue Ala 477 is hydrogen bonded to Cys 425 (9), changes in the strength of the hydrogen bond at Cys 425 as probed by the SH stretching vibration are expected to reflect changes in the interaction between the  $\alpha$ -amine group of the agonist and the protein. It should be noted that the GluR2-S1S2 protein has two non-disulphide bonded cysteines, Cys 436 and Cys 425. However, Cys 436 is far from the ligand binding site, and the SH stretching vibration of this residue does not change between the various ligated states (14). Thus the difference spectrum between the agonist and apo state reflects changes in the frequency of the SH stretch of Cys 425. This has been further verified by studies with GluR4-S1S2 which contains a single non-disulphide bonded cysteine that is at the Cys 425 position (426 in GluR4) (14,15).

In the difference spectra in the region of the SH stretching mode (Figure 4), the difference spectra are obtained between the agonist and apo state; hence the positive band corresponds to the frequency of the SH stretching vibration of Cys 425 in the bound state while the negative band corresponds to its frequency in the apo state. In the wild type protein both AMPA and glutamate induce a large  $18\text{ cm}^{-1}$  downshift in the SH stretch relative to the apo state, while kainate has no effect. This downshift indicates a stronger hydrogen bond at Cys 425 upon binding AMPA/glutamate relative to that in the apo state and can be attributed to strong interactions between the  $\alpha$ -amine group of AMPA/glutamate and the protein, while the lack of changes due to kainate binding suggests weak interactions at the  $\alpha$ -amine group of kainate with the protein (14). Along the same lines, in the case of the Y450F, the shifts follow the order AMPA>kainate>glutamate, which would imply that the strength of the interactions follows the order AMPA>kainate>glutamate, and in the case of the L650T mutation, the shifts follow the order glutamate>kainate>AMPA, which would imply that the strength of the interactions follows the same order.

### **Tug-of-war between $\alpha$ -carboxylate and $\alpha$ -amine group of ligand**

In the case of the wild type protein, the strength of the interactions at the  $\alpha$ -carboxylate of the ligand follows the order, kainate>AMPA>glutamate, which has an inverse correlation to the changes in the strength of the interactions at the  $\alpha$ -amine group that follows the order glutamate $\approx$ AMPA>kainate (14). Similar trends are seen for kainate induced differences between the mutant and wild type protein (Table 2), where a large downshift in the SH stretching vibrational frequency between the kainate and apo forms of the protein is accompanied by a smaller downshift of the asymmetric stretching vibrational band of the  $\alpha$ -carboxylate in the protein relative to the unbound. This would be consistent with the observation in the wild type protein where an increase in the interactions at the  $\alpha$ -amine group is accompanied by a decrease in interactions at the  $\alpha$ -carboxylate. AMPA and glutamate binding to the proteins exhibit smaller shifts in the  $\alpha$ -carboxylate vibrational mode as a result of larger changes at the  $\alpha$ -amine group relative to those observed for kainate (Table 2). This could be a reflection of the larger steric constraints of kainate in the AMPA receptor binding site relative to AMPA and glutamate. Although the magnitude of the changes at the  $\alpha$ -



carboxylate vibrational mode is different for the three agonists glutamate, AMPA, and kainate, similar trends, where an increase in the interactions at the  $\alpha$ -amine group results in a decrease in the interactions at the  $\alpha$ -carboxylate, are observed for all the agonists in both the wild type and two mutant proteins.

### Correlation between ligand environment, cleft closure, and activation in the glutamate receptor

The vibrational spectra, with the exception of glutamate binding to Y450F, show a correlation between the strength of the interactions at the  $\alpha$ -amine group and activation of the receptor, such that a stronger interaction at the  $\alpha$ -amine group results in a larger activation of the channel. The L650T mutation in particular is interesting because in this mutant the extent of cleft closure upon agonist binding does not exhibit the same correlation to activation as seen in the wild type and other mutant proteins (20). Here, we show that while the extent of cleft closure does not correlate to the degree of activation in the L650T mutant, the strength of the interactions at the  $\alpha$ -amine group follows the same trend in this mutant as in the wild type and the AMPA- and kainate-bound forms of the Y450F mutant. Hence AMPA, a partial agonist at this mutant, has weak interactions at the  $\alpha$ -amine group, while glutamate, a full agonist at this mutant, exhibits stronger interactions at the  $\alpha$ -amine group. These results suggest that the interactions between the  $\alpha$ -amine group of the agonist and the protein is an important point of communication between the agonist and protein and an important player in the allosteric pathway of agonist induced receptor activation.

The only exception to the correlation between the shift in the SH stretching frequency and the degree of activation is the glutamate bound form of the Y450F mutant. In this case, glutamate is a full agonist and yet shows a lack of change at the SH stretching vibration. The lack of a change at the SH stretching vibration could result from the greater flexibility in this mutant due to the loss in the hydrogen bonding network on the domain 1 side of the cleft resulting in a loss of the correlation between changes at Cys 425 and the strength of interactions at the  $\alpha$ -amine group of glutamate, and/or it is also possible that the lack of a shift in the SH frequency reflects weak interactions at the  $\alpha$ -amine group of glutamate and that glutamate activation of this mutant is controlled by a different mechanism involving other controls that mediate agonist induced activation.

The large number of X-ray structures of the isolated ligand binding domain in complex with various agonists (7,9,10,18) clearly indicate that the cleft closure conformational change plays an important role in mediating agonist induced receptor activation in the glutamate receptor. The breakdown in the correlation between extent of cleft closure and activation for L650T-S1S2, however, suggests that in addition to the cleft closure conformation, subtle differences in extent of activation could be controlled by other mediators. Here we show that the strength of interactions at the  $\alpha$ -amine group of the agonist could be one such mediator since in eight out of the nine cases studied the extent of the interactions at this moiety correlates to the extent of activation.

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

### Acknowledgements

This work was supported by National Science Foundation grant MCB-04444352, National Institutes of Health Grants R21NS051378, R03AA015682-01, and R01GM073102, and the Muscular Dystrophy Association. K.A.M. was supported by National Institutes of Health Molecular Biophysics Training Grant T32 GM008280.


## Abbreviations

<b>AMPA</b>	$\alpha$ -amino-5-methyl-3-hydroxy-4-isoxazolepropionic acid
<b>GluR2</b>	glutamate receptor subunit 2
<b>GluR4</b>	glutamate receptor subunit 4
<b>FRET</b>	fluorescence resonance energy transfer
<b>FTIR</b>	Fourier transform infrared
<b>NMR</b>	nuclear magnetic resonance

## References


- Hollmann M, Heinemann S. Cloned glutamate receptors. *Annual Review of Neuroscience* 1994;17:31–108.
- Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. *Pharmacological Reviews* 1999;51:7–61. [PubMed: 10049997]
- Madden DR. The structure and function of glutamate receptor ion channels. *Nat Rev Neurosci* 2002;3:91–101. [PubMed: 11836517]
- McFeeters RL, Oswald RE. Emerging structural explanations of ionotropic glutamate receptor function. *Faseb J* 2004;18:428–38. [PubMed: 15003989]
- Oswald RE. Ionotropic glutamate receptor recognition and activation. *Adv Protein Chem* 2004;68:313–49. [PubMed: 15500865]
- Mayer ML. Glutamate receptors at atomic resolution. *Nature* 2006;440:456–62. [PubMed: 16554805]
- Jin R, Horning M, Mayer ML, Gouaux E. Mechanism of activation and selectivity in a ligand-gated ion channel: structural and functional studies of GluR2 and quisqualate. *Biochemistry* 2002;41:15635–43. [PubMed: 12501192]
- Armstrong N, Sun Y, Chen GQ, Gouaux E. Structure of a glutamate-receptor ligand-binding core in complex with kainate. *Nature* 1998;395:913–7. [PubMed: 9804426]
- Armstrong NA, Gouaux E. Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core. *Neuron* 2000;28:165–181. [PubMed: 11086992]
- Jin R, Banke TG, Mayer ML, Traynelis SF, Gouaux E. Structural basis for partial agonist action at ionotropic glutamate receptors. *Nat Neurosci* 2003;6:803–10. [PubMed: 12872125]
- McFeeters RL, Oswald RE. Structural mobility of the extracellular ligand-binding core of an ionotropic glutamate receptor. Analysis of NMR relaxation dynamics. *Biochemistry* 2002;41:10472–81. [PubMed: 12173934]
- McFeeters RL, Swapna GV, Montelione GT, Oswald RE. Semiautomated backbone resonance assignments of the extracellular ligand-binding domain of an ionotropic glutamate receptor. *J Biomol NMR* 2002;22:297–8. [PubMed: 11991359]
- Valentine ER, Palmer AG 3rd. Microsecond-to-millisecond conformational dynamics demarcate the GluR2 glutamate receptor bound to agonists glutamate, quisqualate, and AMPA. *Biochemistry* 2005;44:3410–7. [PubMed: 15736951]
- Cheng Q, Jayaraman V. Chemistry and conformation of the ligand-binding domain of GluR2 subtype of glutamate receptors. *J Biol Chem* 2004;279:26346–50. [PubMed: 15100219]

15. Jayaraman V, Keeseey R, Madden DR. Ligand--protein interactions in the glutamate receptor. *Biochemistry* 2000;39:8693–7. [PubMed: 10913279]
16. Cheng Q, Du M, Ramanoudjame G, Jayaraman V. Evolution of glutamate interactions during binding to a glutamate receptor. *Nat Chem Biol* 2005;1:329–32. [PubMed: 16408071]
17. Pentikainen OT, Settimo L, Keinänen K, Johnson MS. Selective agonist binding of (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA) and 2S-(2 $\alpha$ ,3 $\beta$ ,4 $\beta$ )-2-carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid (kainate) receptors: a molecular modeling study. *Biochem Pharmacol* 2003;66:2413–25. [PubMed: 14637199]
18. Armstrong N, Mayer M, Gouaux E. Tuning activation of the AMPA-sensitive GluR2 ion channel by genetic adjustment of agonist-induced conformational changes. *Proc Natl Acad Sci U S A* 2003;100:5736–41. [PubMed: 12730367]
19. Holm MM, Naur P, Vestergaard B, Geballe MT, Gajhede M, Kastrup JS, Traynelis SF, Egebjerg J. A binding site tyrosine shapes desensitization kinetics and agonist potency at GluR2. A mutagenic, kinetic, and crystallographic study. *J Biol Chem* 2005;280:35469–76. [PubMed: 16103115]
20. Ramanoudjame G, Du M, Mankiewicz KA, Jayaraman V. Allosteric mechanism in AMPA receptors: A FRET-based investigation of conformational changes. *Proc Natl Acad Sci U S A* 2006;103:10473–8. [PubMed: 16793923]
21. Cheng Q, Thiran S, Yernool D, Gouaux E, Jayaraman V. A vibrational spectroscopic investigation of interactions of agonists with GluR0, a prokaryotic glutamate receptor. *Biochemistry* 2002;41:1602–8. [PubMed: 11814354]
22. Du M, Reid SA, Jayaraman V. Conformational changes in the ligand-binding domain of a functional ionotropic glutamate receptor. *J Biol Chem* 2005;280:8633–6. [PubMed: 15632199]
23. Jayaraman V. Spectroscopic and kinetic methods for ligand-protein interactions of glutamate receptor. *Methods Enzymol* 2004;380:170–87. [PubMed: 15051337]
24. Madden DR, Cheng Q, Thiran S, Rajan S, Rigo F, Keinänen K, Reinelt S, Zimmermann H, Jayaraman V. Stereochemistry of glutamate receptor agonist efficacy: engineering a dual-specificity AMPA/kainate receptor. *Biochemistry* 2004;43:15838–44. [PubMed: 15595838]
25. Chapman D, Jackson M, Haris PI. Investigation of Membrane-Protein Structure Using Fourier-Transform Infrared-Spectroscopy. *Biochemical Society Transactions* 1989;17:617–619. [PubMed: 2670628]




**Fig. 1. Electrophysiology for wild-type and Y450F**

(A) Whole cell current recordings of wild-type and Y450F expressed in HEK 293 cells resulting from exposure to 10 mM glutamate, 10 mM kainate, and 5 mM AMPA with 100  $\mu$ M cyclothiazide. (B) The maximum currents resulting from glutamate, AMPA, and kainate normalized to the currents mediated by 10 mM AMPA for the wild-type and Y450F and to 10 mM glutamate for L650T.



**Fig. 2. Cleft closure in wild type, Y450F-S1S2, and L650T-S1S2**


Distances between T394C and S652C as measured by fluorescence resonance energy transfer for the wild type (open circles), S1S2-Y450F mutant (filled squares), and S1S2-L650T mutant (open triangles) plotted as a function of extent of activation.



**Fig. 3. Changes at the  $\alpha$ -carboxylate and secondary structural modes**

Difference FTIR spectra in the region of  $1560\text{ cm}^{-1}$  to  $1740\text{ cm}^{-1}$  between agonist-bound wild type S1S2 and unligated S1S2, agonist-bound S1S2-Y450F and unligated S1S2-Y450F, and agonist bound-L650T and unligated S1S2-L650T for the three agonists AMPA, glutamate, and kainate.





**Fig. 4. Changes at the Cys 425 SH stretching mode**

Difference FTIR spectra in the region of 2500 cm<sup>-1</sup> to 2600 cm<sup>-1</sup> between agonist-bound wild type S1S2 and apo S1S2, agonist bound S1S2-Y450F and apo S1S2-Y450F, and agonist bound S1S2-L650T and apo S1S2-L650T for the three agonists AMPA, glutamate, and kainate.

**Table 1****Lifetime measurements for Y450F-S1S2**

Fluorescence lifetimes for the Y450F-S1S2 (T394C;S652C) tagged with terbium chelate ( $\tau_D$ ), and Y450F-S1S2 (T394C;S652C) tagged with a 1:1 ratio of terbium chelate and fluorescein( $\tau_{DA}$ ).

Ligated state	$\tau_D$ (ns)	$\tau_{DA}$ (ns)
Apo	1565 $\pm$ 23	242 $\pm$ 2.7
Glutamate	1515 $\pm$ 15	140 $\pm$ 1.7
AMPA	1515 $\pm$ 13	131 $\pm$ 1.8
Kainate	1543 $\pm$ 19	166 $\pm$ 2.0

**Table 2****Frequency shifts for wild type, S1S2-Y450F, and S1S2-L650T**

Shift in the frequency of the  $\alpha$ -carboxylate asymmetric stretching vibration of the agonist bound to the protein relative to its frequency in buffer and of the Cys 425 SH stretching vibration in the agonist-bound state relative to the apo state.

Protein-Agonist	$\alpha$ -carboxylate shift	SH shift
WT-AMPA	9	18
Y450F-AMPA	9	20
L650T-AMPA	10	0
WT-Glutamate	4	18
Y450F-Glutamate	5	0
L650T-Glutamate	4	20
WT-Kainate	18	0
Y450F-Kainate	14	11
L650T-Kainate	13	16